Allogene Therapeutics Inc.

Allogene Therapeutics is a US-based, clinical-stage, biotechnology healthcare company focussed on developing cancer treatments. The firm’s research is based on the development of allogeneic chimeric antigen receptor T-cell therapies. Founded in 2017, Allogene Therapeutics is based in San Francisco, California and is working to provide therapeutic treatments to patients worldwide who are living with hematologic cancers and solid tumours. Allogene trades on the NASDAQ GS with the ticker ALLO. The company launched its IPO in October 2018 with what was generally considered to be one of the biggest and most lucrative public offerings in over a decade, raising $324m and resulting in a market value of over $2bn. ALLO stock rose more than 30% on its first day of public trading. The company’s successful IPO was no doubt fuelled by previous well-publicised successes. In April 2018, the firm acquired Pfizer’s allogeneic CAR T portfolio and closed its Series A round of venture capital financing, raising $300m from a premium investment consortium made up of some of the leading names in biotechnology, such as Gilead and Pfizer. Are you considering investing in this instrument? Get news and updates on price changes by adding ATT stock to your eToro watchlist now.